Antonio Gil-Nagel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9343165/publications.pdf

Version: 2024-02-01

103 papers

3,937 citations

147801 31 h-index 57 g-index

108 all docs 108 docs citations

108 times ranked 4484 citing authors

#	Article	IF	CITATIONS
1	Fenfluramine significantly reduces dayâ€toâ€day seizure burden by increasing number of seizureâ€free days and time between seizures in patients with Dravet syndrome: A timeâ€toâ€event analysis. Epilepsia, 2022, 63, 130-138.	5.1	22
2	DNA methylation-based classification of malformations of cortical development in the human brain. Acta Neuropathologica, 2022, 143, 93-104.	7.7	18
3	Epilepsy Genetics and Precision Medicine in Adults: A New Landscape for Developmental and Epileptic Encephalopathies. Frontiers in Neurology, 2022, 13, 777115.	2.4	21
4	Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome. JAMA Neurology, 2022, 79, 554.	9.0	43
5	The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis. Epilepsy and Behavior, 2022, 132, 108711.	1.7	3
6	Epilepsy Associated with Temporal Pole Encephaloceles. Clinical Neuroradiology, 2021, 31, 575-579.	1.9	14
7	Epidaily, a scale for comprehensive functional assessment of patients with epilepsy. Epilepsy and Behavior, 2021, 114, 107570.	1.7	O
8	Initiating antiepilepsy treatment: An update of expert consensus in Spain. Epilepsy and Behavior, 2021, 114, 107540.	1.7	5
9	Contributions of left and right anterior temporal lobes to semantic cognition: Evidence from patients with small temporopolar lesions. Neuropsychologia, 2021, 152, 107738.	1.6	2
10	Impact of COVID-19 on the lives and psychosocial well-being of persons with epilepsy during the third trimester of the pandemic: Results from an international, online survey. Epilepsy and Behavior, 2021, 116, 107800.	1.7	16
11	Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohort. Epilepsy and Behavior, 2021, 118, 107946.	1.7	9
12	Longâ€ŧerm safety and efficacy of addâ€on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a longâ€ŧerm open″abel extension trial. Epilepsia, 2021, 62, 2228-2239.	5.1	52
13	Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. Epilepsy and Behavior, 2021, 122, 108212.	1.7	9
14	Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA). Epilepsy and Behavior, 2021, 122, 108222.	1.7	9
15	Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure: the Journal of the British Epilepsy Association, 2021, 93, 154-159.	2.0	41
16	Morphometric correlates of anomia in patients with small left temporopolar lesions. Journal of Neuropsychology, 2020, 14, 260-282.	1.4	3
17	Consensus statement for the management of generalized tonicâ€clonic seizures in Spain. Acta Neurologica Scandinavica, 2020, 141, 22-32.	2.1	2
18	Praxis induction and its relationship with cognition in genetic generalized epilepsy. Epilepsy and Behavior, 2020, 102, 106638.	1.7	1

#	Article	IF	CITATIONS
19	Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens. JAMA Neurology, 2020, 77, 300.	9.0	152
20	Trends in pediatric epilepsy surgery in Europe between 2008 and 2015: Countryâ€, centerâ€, and ageâ€specific variation. Epilepsia, 2020, 61, 216-227.	5.1	44
21	Temporal pole epilepsy: Do not forget to look for occult encephaloceles. Epilepsia, 2020, 61, 2859-2860.	5.1	3
22	Corticospinal tract displacement due to a large malformation during cortical development. Epileptic Disorders, 2020, 22, 695-696.	1.3	1
23	A European questionnaire survey on epilepsy monitoring units' current practice for postoperative psychogenic nonepileptic seizures' detection. Epilepsy and Behavior, 2020, 112, 107355.	1.7	2
24	Herpes simplex virus encephalitis after temporal lobe resection: an infrequent but treatable complication of epilepsy surgery. European Journal of Neurology, 2020, 27, e60-e61.	3.3	0
25	Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study. Lancet Neurology, The, 2020, 19, 748-757.	10.2	177
26	EEG in fitness to drive evaluations in people with epilepsy â€" Considerable variations across Europe. Seizure: the Journal of the British Epilepsy Association, 2020, 79, 56-60.	2.0	2
27	Genetic epilepsies and COVIDâ€19 pandemic: Lessons from the caregiver perspective. Epilepsia, 2020, 61, 1312-1314.	5.1	41
28	Antiseizure medication withdrawal in seizure-free patients with PCDH19-related epilepsy: A multinational cohort survey. Seizure: the Journal of the British Epilepsy Association, 2020, 80, 259-261.	2.0	5
29	Effectiveness and safety of perampanel monotherapy for focal and generalized tonicâ€clonic seizures: Experience from a national multicenter registry. Epilepsia, 2020, 61, 1109-1119.	5.1	27
30	Could the 2017 ILAE and the four-dimensional epilepsy classifications be merged to a new "Integrated Epilepsy Classification�. Seizure: the Journal of the British Epilepsy Association, 2020, 78, 31-37.	2.0	18
31	Diagnostic gap in genetic epilepsies: A matter of age. Epilepsy and Behavior, 2020, 111, 107266.	1.7	10
32	Mnemonic discrimination in patients with unilateral mesial temporal lobe epilepsy relates to similarity and number of events stored in memory. Neurobiology of Learning and Memory, 2020, 169, 107177.	1.9	9
33	From theory to practice: Critical points in the 2017 ILAE classification of epileptic seizures and epilepsies. Epilepsia, 2020, 61, 350-353.	5.1	5
34	Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome. JAMA Neurology, 2020, 77, 613.	9.0	171
35	Adverse effects of cannabinoids. Epileptic Disorders, 2020, 22, 29-32.	1.3	6
36	Epilepsy and cannabidiol: a guide to treatment. , 2020, 22, 1-14.		46

#	Article	IF	CITATIONS
37	Olfactory function in focal epilepsies: Understanding mesial temporal lobe epilepsy beyond the hippocampus. Epilepsia Open, 2019, 4, 487-492.	2.4	14
38	Patients' knowledge on epilepsy and SUDEP improves after a semi-structured health interview. Epilepsy and Behavior, 2019, 99, 106467.	1.7	10
39	The Surgical Approach to the Anterior Nucleus of Thalamus in Patients With Refractory Epilepsy: Experience from the International Multicenter Registry (MORE). Neurosurgery, 2019, 84, 141-150.	1.1	57
40	Specificity of electroclinical features in the diagnosis of ring chromosome 20. Epilepsy and Behavior, 2018, 80, 215-220.	1.7	12
41	Retrospective study of perampanel efficacy and tolerability in myoclonic seizures. Acta Neurologica Scandinavica, 2018, 138, 122-129.	2.1	23
42	Epidemiological profile of epilepsy in low income populations. Seizure: the Journal of the British Epilepsy Association, 2018, 56, 67-72.	2.0	85
43	A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2018, 54, 61-66.	2.0	49
44	Genetic (idiopathic) generalized epilepsy with occipital semiology. Epileptic Disorders, 2018, 20, 434-439.	1.3	8
45	Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Frontal Lobe Epilepsy: A New Clinicoâ€Pathological Entity. Brain Pathology, 2017, 27, 26-35.	4.1	81
46	Current standards of neuropsychological assessment in epilepsy surgery centers across Europe. Epilepsia, 2017, 58, 343-355.	5.1	69
47	Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. New England Journal of Medicine, 2017, 377, 1648-1656.	27.0	621
48	Lacosamide for refractory generalized tonic–clonic seizures of non-focal origin in clinical practice: A clinical and VEEG study. Epilepsy & Behavior Case Reports, 2017, 8, 63-65.	1.5	16
49	Pooled efficacy and safety of eslicarbazepine acetate as addâ€on treatment in patients with focalâ€onset seizures: Data from four doubleâ€blind placeboâ€controlled pivotal phase <scp>III</scp> clinical studies. CNS Neuroscience and Therapeutics, 2017, 23, 961-972.	3.9	25
50	Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study. Epilepsy and Behavior, 2017, 73, 173-179.	1.7	19
51	Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes. PLoS ONE, 2017, 12, e0188978.	2.5	56
52	Small temporal pole encephalocele: A hidden cause of "normal― <scp>MRI</scp> temporal lobe epilepsy. Epilepsia, 2016, 57, 841-851.	5.1	56
53	Current use of imaging and electromagnetic source localization procedures in epilepsy surgery centers across Europe. Epilepsia, 2016, 57, 770-776.	5.1	89
54	Current practices in long-term video-EEG monitoring services: A survey among partners of the E-PILEPSY pilot network of reference for refractory epilepsy and epilepsy surgery. Seizure: the Journal of the British Epilepsy Association, 2016, 38, 38-45.	2.0	67

#	Article	IF	CITATIONS
55	Serial arterial spin labeling MRI in autonomic status epilepticus due to anti-LGI1 encephalitis. Neurology, 2016, 87, 443-444.	1.1	12
56	Testing patients during seizures: A European consensus procedure developed by a joint taskforce of the ⟨scp⟩ILAE⟨ scp⟩ â€" Commission on European Affairs and the European Epilepsy Monitoring Unit Association. Epilepsia, 2016, 57, 1363-1368.	5.1	51
57	A fast pathway for fear in human amygdala. Nature Neuroscience, 2016, 19, 1041-1049.	14.8	276
58	Visual object naming in patients with small lesions centered at the left temporopolar region. Brain Structure and Function, 2016, 221, 473-485.	2.3	13
59	Altered brain rhythms and functional network disruptions involved in patients with generalized fixation-off epilepsy. Brain Imaging and Behavior, 2016, 10, 373-386.	2.1	8
60	Differences in visual naming performance between patients with temporal lobe epilepsy associated with temporopolar lesions versus hippocampal sclerosis Neuropsychology, 2016, 30, 841-852.	1.3	6
61	Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy and Behavior, 2015, 52, 119-127.	1.7	70
62	Prevalence of depressive symptoms and their impact on quality of life in patients with drug-resistant focal epilepsy (IMDYVA study). Epilepsy Research, 2015, 110, 157-165.	1.6	34
63	A European survey on current practices in epilepsy monitoring units and implications for patients' safety. Epilepsy and Behavior, 2015, 44, 179-184.	1.7	45
64	Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: A multicenter evaluation. Seizure: the Journal of the British Epilepsy Association, 2015, 29, 119-122.	2.0	17
65	Immunomodulated parkinsonism as a presenting symptom of LGI1 antibody encephalitis. Parkinsonism and Related Disorders, 2015, 21, 1286-1287.	2.2	20
66	Time to prerandomization monthly seizure count in perampanel trials. Neurology, 2015, 84, 2014-2020.	1.1	32
67	Network reconfiguration and working memory impairment in mesial temporal lobe epilepsy. Neurolmage, 2013, 72, 48-54.	4.2	46
68	Treatment of behavioral problems in intellectually disabled adult patients with epilepsy. Epilepsia, 2013, 54, 34-40.	5.1	27
69	Aphasic seizures in patients with temporopolar and anterior temporobasal lesions: A video-EEG study. Epilepsy and Behavior, 2013, 29, 172-177.	1.7	16
70	Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures. Epilepsy Research, 2013, 107, 138-145.	1.6	14
71	Efficacy and safety of eslicarbazepine acetate as addâ€on treatment in patients with focalâ€onset seizures: Integrated analysis of pooled data from doubleâ€blind phase III clinical studies. Epilepsia, 2013, 54, 98-107.	5.1	85
72	Anterobasal Temporal Lobe Lesions Alter Recurrent Functional Connectivity within the Ventral Pathway during Naming. Journal of Neuroscience, 2013, 33, 12679-12688.	3.6	32

#	Article	IF	Citations
73	Remote Effects of Hippocampal Sclerosis on Effective Connectivity during Working Memory Encoding: A Case of Connectional Diaschisis?. Cerebral Cortex, 2012, 22, 1225-1236.	2.9	56
74	Validation of the Spanish version of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E). Epilepsy and Behavior, 2012, 24, 493-496.	1.7	56
75	Retigabine as adjunctive therapy in adults with partial-onset seizures: Integrated analysis of three pivotal controlled trials. Epilepsy Research, 2012, 101, 103-112.	1.6	35
76	Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies. Epilepsy Research, 2012, 102, 117-121.	1.6	25
77	Electroencephalography and video-electroencephalography. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 107, 323-345.	1.8	11
78	Antiepileptic drug therapy: Does mechanism of action matter?. Epilepsy and Behavior, 2011, 21, 490.	1.7	8
79	Antiepileptic drug therapy: Does mechanism of action matter?. Epilepsy and Behavior, 2011, 21, 331-341.	1.7	117
80	Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 801-804.	2.0	20
81	Eficacia de la monitorización videoelectroencefalográfica prolongada con protocolo especÃfico de activación cerebral en el diagnóstico diferencial de la epilepsia. Revista CientÃfica De La Sociedad Española De EnfermerÃa Neurológica, 2011, 33, 5-9.	0.1	0
82	Bilateral akinetic seizures: A clinical and electroencephalographic description. Epilepsia, 2010, 51, 2108-2115.	5.1	4
83	A graded system to categorize drugâ€resistant epilepsy. Epilepsia, 2010, 51, 2360-2361.	5.1	19
84	Familial Recurrent Hypersomnia: Two Siblings with Kleine-Levin Syndrome and Menstrual-Related Hypersomnia. Journal of Child Neurology, 2010, 25, 1408-1410.	1.4	31
85	Modulation of medial temporal lobe activity in epilepsy patients with hippocampal sclerosis during verbal working memory. Journal of the International Neuropsychological Society, 2009, 15, 536-546.	1.8	15
86	Add-on treatment with pregabalin for partial seizures with or without generalisation: Pooled data analysis of four randomised placebo-controlled trials. Seizure: the Journal of the British Epilepsy Association, 2009, 18, 184-192.	2.0	28
87	Erratum to "Add-on treatment with pregabalin for partial seizures with or without generalisation: Pooled data analysis of four randomised placebo-controlled trials―[Seizure: European Journal of Epilepsy 18 (2009) 184–192]. Seizure: the Journal of the British Epilepsy Association, 2009, 18, 719.	2.0	0
88	Validation of the Spanish version of the Side Effect and Life Satisfaction Inventory in patients with epilepsy. Epilepsy and Behavior, 2009, 14, 96-101.	1.7	5
89	A clinical and magnetoencephalography study of MRI-negative startle epilepsy. Epilepsy and Behavior, 2009, 16, 166-171.	1.7	32
90	Adverse Effects of Antiepileptic Drugs. Seminars in Neurology, 2008, 28, 317-327.	1.4	125

#	Article	IF	CITATIONS
91	Hypnagogic Behavior Disorder: Complex Motor Behaviors During Wake–Sleep Transitions in 2 Young Children. Journal of Child Neurology, 2008, 23, 959-963.	1.4	0
92	Risks and Benefits of Generic Antiepileptic Drugs. Neurologist, 2008, 14, S66-S72.	0.7	5
93	Editorial. Neurologist, 2008, 14, S1.	0.7	O
94	Epilepsy in Inherited Metabolic Disorders. Neurologist, 2008, 14, S2-S14.	0.7	31
95	7 Antiepileptic drugs. Side Effects of Drugs Annual, 2007, 29, 87-104.	0.6	O
96	Diagnostic Problems in the Initial Assessment of Epilepsy. Neurologist, 2007, 13, S2-S10.	0.7	5
97	Surgery and Electrical Stimulation in Epilepsy. Neurologist, 2007, 13, S29-S37.	0.7	8
98	Antiepileptic Drugs. Neurologist, 2007, 13, S20-S28.	0.7	21
99	Occipital lobe epilepsy secondary to ulegyria. Journal of Neurology, 2005, 252, 1178-1185.	3.6	22
100	Neurodevelopmental liabilities in epilepsy. Neurotoxicity Research, 2003, 5, 45-51.	2.7	2
101	Review of New Antiepileptic Drugs as Initial Therapy. Epilepsia, 2003, 44, 3-10.	5.1	29
102	The Localizing Yield of Sphenoidal and Anterior Temporal Electrodes in Ictal Recordings: A Comparison Study. Epilepsia, 2002, 43, 1189-1196.	5.1	30
103	When Should Induction Protocols Be Used in the Diagnostic Evaluation of Patients with Paroxysmal Events?. Epilepsia, 1998, 39, 863-867.	5.1	47